Arkolith/Insider Trading/RPRX/Form 4

Legorreta Pablo G.

CEO, Chairman of the Board, DirectorRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Aug 8, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 6, 2025Grant(A)22K—$0904K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 8, 2025Gift(G)60K—$0693K

Transaction Codes

A
Grant / award
G
Gift

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001802768-25-000105) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML